Lilly Cymbalta manufacturing remains delayed
Lilly receives second "approvable" letter for Cymbalta (duloxetine) Sept. 29 citing manufacturing issues still to be resolved. Lilly expects FDA's overall assessment of GMP compliance in its Indianapolis plants by year-end. Cymbalta approval is also contingent on labeling negotiations. No more trials will be necessary for Cymbalta, which had been a concern following an "approvable" letter for duloxetine's stress urinary incontinence indication requesting additional studies (1"The Pink Sheet" Sept. 8, 2003, p. 4)...
You may also be interested in...
Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory
Lilly's plans to launch Cymbalta at the start of 2004 appear to hinge on the company's ability to convince FDA that the drug interaction issues delaying approval of duloxetine for incontinence should not hold up availability of the drug for depression
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.